Floatz logo

Guselkumab

Psoriasis (PsO)

University of California, San Diegomonoclonal_antibodyActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
95/ 100

Competitive context

12 Active assets in the Psoriasis (PsO) cohort.

Asset / SponsorPhaseRating
1-235-TUMOR NECROSIS FACTOR RECEPTOR (HUMAN) FUSION PROTEIN WITH 236-467-IMMUNOGLOBULIN G1 (HUMAN .GAMMA.1-CHAIN FC FRAGMENT), DIMER
Amgen
Phase 4BBB
Calcipotriene
Hospital Universitario Dr. Jose E. Gonzalez
Phase 4BBB
Semaglutide
Hospital Universitario Dr. Jose E. Gonzalez
Phase 4BBB
Tirzepatide
Eli Lilly and Company
Phase 4BBB
cp-690,550
Pfizer
Phase 3BBB

View all 28 →

Same molecule, other indications

Guselkumab is also rated in:

classic familial adenomatous polyposisDormant
CC
Indicative ·
47 / 100
View asset →
celiac diseaseDormant
CC
Indicative ·
43 / 100
View asset →
psoriatic arthritisDormant
D
Indicative ·
30 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →